admin, Author at Dr Chaitana Joshi, MD

Newborn examination form Summary!

NEWBORN EXAMINATION FORM Continue reading Newborn examination form Summary!

Causes of Anemia in Infants : The Shortcut and Mnemonics in Anemia Causes

Causes of Anemia in Infants (List Only):

1. Nutritional causes

Iron deficiency
Vitamin B12 deficiency
Folate deficiency
Protein-energy malnutrition

2. Blood loss

Gastrointestinal bleeding (e.g., anal fissure, Meckel’s diverticulum
Birth trauma or internal hemorrhage
Iatrogenic blood loss (frequent phlebotomy in NICU)
Occult bleeding (cow’s milk protein-induced colitis)

3. Hemolytic causes

Hemolytic disease of the newborn (Rh or ABO incompatibility)
G6PD deficiency
Hereditary spherocytosis
Thalassemia
Sickle cell disease
Infections causing hemolysis (e.g., malaria, sepsis)

4. Bone marrow failure / decreased production

Aplastic anemia
Congenital pure red cell aplasia (Diamond–Blackfan anemia)
Transient erythroblastopenia of childhood
Bone marrow infiltration (leukemia, storage diseases)

5. Chronic disease / inflammation

Anemia of chronic infection or inflammation
Renal failure (↓ erythropoietin)

6. Physiologic / other causes

Physiologic anemia of infancy
Prematurity (low iron stores, immature erythropoiesis)
Hypothyroidism
Chronic blood loss from parasites (hookworm in older infants)

Note on Anaphylaxis

Note on anaphylaxis

How to store breast milk for future use?

1. Purpose

Proper storage of expressed breast milk (EBM) helps preserve its nutritional and immunological properties for later feeding when the mother is away.

2. Containers for Storage

Use clean, sterilized glass or BPA-free plastic containers with tight-fitting lids.
Breast milk storage bags (food-grade, pre-sterilized) are convenient for freezing.
Avoid ordinary plastic bottles or disposable liners.

3. Labeling

Each container should be labeled with:
Date and time of expression
Baby’s name (if used in hospital or daycare)

4. Storage Guidelines

Location	Temperature	Duration	Remarks
Room temperature	Up to 25°C (77°F)	4–6 hours	Keep in a cool, clean area away from direct sunlight
Refrigerator (back portion)	2–4°C (35–40°F)	Up to 72 hours (3 days)	Do not store in refrigerator door due to temperature fluctuation
Freezer (separate door)	–18°C or lower	Up to 3–6 months	Keep in small portions; leave space for expansion
Deep freezer	–20°C	Up to 6–12 months	Best for long-term storage
Insulated cooler box with ice packs	~15°C	Up to 24 hours	For temporary transport or travel

5. Thawing and Warming

Thaw in refrigerator overnight or by placing the container in warm water (<37°C).
Do not microwave or boil — destroys antibodies and nutrients.
Swirl gently (do not shake) to mix separated fat layers.
Once thawed, use within 24 hours and do not refreeze.

6. Hygiene

Wash hands before expressing or handling milk.
Use clean pump parts and containers for each session.
Avoid touching the inside of lids or bottles.

7. Key Points

Always use oldest milk first (“first in, first out”).
Discard leftover milk from feeding bottle after use.
Observe for odor or curdling — discard if spoiled.

Summary:

Safe breast milk storage requires hygienic handling, correct temperature, and appropriate duration. Properly stored milk retains most of its nutritional, immunological, and protective properties, ensuring safe feeding for infants when direct breastfeeding isn’t possible.

What causes Large and Thick placenta (placentomegaly)?

Placentomegaly — Causes

~~Table of Contents(toc)~~

Definition:

Placentomegaly refers to an abnormally thick or enlarged placenta, typically defined as:

>4 cm thick at 20 weeks gestation, or
>6 cm thick at term.

plaenta normal anterior image

I. Maternal Causes

Diabetes mellitus (especially poorly controlled)

→ due to villous edema and increased fetal size.
Maternal anemia (especially severe)

→ compensatory placental hypertrophy to improve oxygen transfer.
Maternal infection
- TORCH infections (Toxoplasmosis, Rubella, CMV, Herpes)
- Syphilis, Malaria, Hepatitis, HIV
Hypertension with superimposed infection or diabetes
Rh isoimmunization (leading to fetal hydrops and placental edema)

II. Fetal Causes

Fetal hydrops (immune or non-immune)
- Most common fetal cause.
- Due to excessive fluid accumulation → placental edema.
Chromosomal abnormalities
- Trisomy 13, 18, 21, Triploidy, Turner syndrome
Fetal anemia (any cause, e.g., parvovirus B19 infection)
Twin-to-twin transfusion syndrome (recipient twin side)
Large-for-gestational-age (LGA) fetus

Often secondary to maternal diabetes.

a large placenta

III. Placental / Cord Causes

Chorioangioma (benign vascular tumor of placenta)
Molar pregnancy (partial mole)
Chronic villitis or placentitis
Placental edema due to venous obstruction (cord anomalies)

IV. Other / Miscellaneous Causes

Congenital infections (CMV, syphilis, toxoplasmosis, parvovirus)
Placental transfusion syndromes
Maternal-fetal hemorrhage
High altitude pregnancies (chronic hypoxia)

Mnemonic (for quick recall):

“BIG PLACENTA”

B – Beta-thalassemia / fetal anemia
I – Infections (TORCH, malaria, syphilis)
G – Gestational diabetes
P – Parvovirus / Polyhydramnios
L – Large baby (LGA)
A – Aneuploidy (Trisomy 13/18/21)
C – Chorioangioma
E – Erythroblastosis fetalis (Rh isoimmunization)
N – Nonimmune hydrops
T – Twin-to-twin transfusion
A – Anemia (maternal or fetal)

An enlarged placenta isn’t usually a reason to panic. The word is big (placentomegaly), but most of the time it doesn’t cause problems.
Some conditions play a role. A larger placenta may be linked to hypertension, anemia, or diabetes — but your doctor will monitor these and the health of your baby.
Your baby’s growth matters most. Even if your placenta measures big, steady fetal development is the important goal, so keep up your regular appointments to be sure everything’s right on track.

Rett Syndrome Notes for MD and DM level

Rett Syndrome

Definition

Rett syndrome is a neurodevelopmental disorder that primarily affects girls, characterized by normal early development followed by regression of acquired skills, especially speech and purposeful hand movements, with onset typically between 6–18 months of age.

Etiology

Genetic cause: Mutation in MECP2 gene (methyl-CpG-binding protein 2) on the X chromosome (Xq28)
Inheritance: Usually sporadic (de novo); rarely familial
Pathophysiology: Dysfunction of MECP2 protein → abnormal brain maturation and synaptic development

Epidemiology

Affects 1 in 10,000–15,000 female births
Lethal in males (most do not survive infancy unless mosaic or XXY)

Clinical Features

Phases of Disease

Early Onset (6–18 months)
- Normal development initially
- Gradual loss of interest in surroundings
- Loss of purposeful hand skills
- Deceleration of head growth (acquired microcephaly)
Rapid Destructive Phase (1–4 years)
- Loss of speech and purposeful hand use
- Stereotyped hand movements: hand-wringing, washing, clapping, or mouthing
- Gait ataxia, truncal apraxia
- Autistic-like behavior
Plateau Phase (2–10 years)
- Some improvement in social interaction and eye contact
- Persistent motor problems and seizures
Late Motor Deterioration (>10 years)
- Progressive scoliosis, muscle wasting, rigidity, dystonia
- Loss of ambulation in many cases

Other Features

Breathing abnormalities: hyperventilation, apnea during wakefulness
Seizures: common (up to 90%)
Bruxism, cold/purple extremities (autonomic dysfunction)
Sleep disturbances
Growth retardation

Investigations

Genetic testing: MECP2 mutation analysis (diagnostic)
EEG: slowing with epileptiform activity
MRI brain: may show nonspecific atrophy
Metabolic tests: normal (to rule out other causes)

Diagnosis

Clinical + confirmed MECP2 mutation
Diagnostic criteria include:
- Regression after normal early development
- Loss of purposeful hand skills and spoken language
- Gait abnormalities
- Stereotypic hand movements

Differential Diagnosis

Autism spectrum disorder
Angelman syndrome
Cerebral palsy (especially ataxic type)
Childhood disintegrative disorder

Management

No cure – supportive and multidisciplinary care
- Physiotherapy & occupational therapy: maintain mobility
- Speech therapy: communication support (eye-tracking devices)
- Antiepileptics: for seizures
- Nutritional support: adequate calories, manage feeding difficulties
- Behavioral therapy: improve interaction
- Orthopedic care: for scoliosis, contractures

Prognosis

Progressive but non-degenerative
Life expectancy: many survive into adulthood (40–50 years)
Main causes of death: sudden unexplained death, pneumonia, cardiac arrhythmias

Mnemonic (Key features) — “RETT”

R = Regression (speech, hand skills)
E = Episodic breathing abnormalities
T = Typical hand movements (wringing, washing)
T = Tiny head (acquired microcephaly)

Hypothyroidism in Neonates and Children

~~Table of Contents(toc)~~

1. Definition

Hypothyroidism is a clinical state resulting from deficiency of thyroid hormone production or action, leading to a generalized slowing of metabolic processes.

It may be:

Congenital (Neonatal) – present at birth.
Acquired (Childhood) – develops later due to autoimmune, iatrogenic, or other causes.

2. Classification

A. Based on Level of Defect

Type	Site of Defect	TSH	T4/T3
Primary	Thyroid gland	↑	↓
Secondary	Pituitary	↓/N	↓
Tertiary	Hypothalamus	↓/N	↓
Peripheral (Resistance)	Target tissue	N/↑	N/↑

B. Based on Onset

Congenital hypothyroidism (CH)
Acquired hypothyroidism

3. Epidemiology

CH: ~1 in 2,000–4,000 live births.
More common in females.
Acquired form common in older children/adolescents, often autoimmune (Hashimoto’s).

thyroid gland

4. Etiology

A. Congenital Hypothyroidism

Thyroid dysgenesis (80–85%)
- Agenesis, ectopy, or hypoplasia.
- Usually sporadic.
Dyshormonogenesis (10–15%)
- Inborn errors of thyroid hormone synthesis (autosomal recessive).
- E.g. TPO, TG, Pendrin, NIS mutations.
Central hypothyroidism (rare)
- Pituitary/hypothalamic malformation, midline defects.
Transient CH
- Iodine excess/deficiency, maternal antibodies or antithyroid drugs.
Thyroid hormone resistance – extremely rare.

B. Acquired Hypothyroidism

Autoimmune thyroiditis (Hashimoto’s) – most common.
Iodine deficiency/excess.
Post-irradiation or post-surgical.
Drugs: amiodarone, lithium, interferon-α.
Secondary causes: pituitary tumors, craniopharyngioma.

5. Pathophysiology

↓ Thyroid hormone → ↓ metabolic activity → impaired CNS myelination, growth retardation, delayed bone maturation.

In neonates: irreversible neurodevelopmental impairment if untreated.
In older children: growth failure and delayed puberty predominate.

6. Clinical Features

A. Neonatal / Congenital

Often asymptomatic at birth due to transplacental maternal T4.

Typical features (develop over weeks):

Prolonged jaundice
Lethargy, hypotonia
Feeding difficulty, constipation
Large fontanelles
Macroglossia
Umbilical hernia
Cold, dry skin
Hoarse cry
Poor growth
Delayed bone age
Delayed milestones (later)

B. Childhood / Acquired

Growth retardation, short stature
Weight gain with poor height velocity
Fatigue, cold intolerance
Constipation
Dry skin, coarse hair
Bradycardia
Delayed puberty / menstrual irregularities
Pseudoprecocious puberty (rare, due to high TRH → prolactin ↑)
Goiter (especially in Hashimoto’s)

7. Investigations

A. Screening

Neonatal screening: heel-prick sample at 48–72 hr.
- Primary TSH (most programs).
- Elevated TSH → confirm with serum free T4.

B. Diagnostic Tests

Test	Interpretation
Serum TSH, Free T4	↓T4 with ↑TSH → primary hypothyroidism
T3	less reliable in neonates
Thyroglobulin	Low in agenesis, high in dyshormonogenesis
Imaging	Thyroid scan (99mTc or I-123) – ectopy, agenesis, uptake defects
Ultrasound	Gland location and size
Antibodies (TPO, Tg)	Positive in autoimmune
Bone age X-ray	Delayed
Additional: Pituitary MRI if central hypothyroidism suspected

8. Complications (if untreated)

Neurologic: irreversible intellectual disability, deaf-mutism, spasticity.
Growth: severe stunting, delayed bone age.
Metabolic: dyslipidemia.
Cardiac: bradycardia, pericardial effusion.

9. Management

A. Principles

Early, adequate, lifelong replacement.
Monitor and titrate carefully to maintain euthyroid state.

B. Drug

Levothyroxine (L-T4) – drug of choice.
- Dose:
  - Neonates: 10–15 µg/kg/day.
  - Infants: 8–10 µg/kg/day.
  - Children: 4–6 µg/kg/day.
  - Adolescents: 2–4 µg/kg/day.
- Given on empty stomach (preferably crushed with water or milk).

C. Monitoring

Age	Frequency	Parameters
0–6 mo	Every 2 wk till T4 normal, then q1–2 mo	T4, TSH
6–12 mo	q2–3 mo	〃
1–3 yr	q3–4 mo	〃
>3 yr	q6–12 mo	〃

Target: Free T4 in upper half of normal range, TSH normal.

D. Developmental Follow-up

Neurodevelopmental assessment
Hearing evaluation
Growth chart monitoring

10. Prognosis

Normal IQ if therapy started within first 2 weeks of life.
Delay in treatment → irreversible intellectual deficit.
Acquired forms usually fully reversible with treatment.

11. Key Differentials

Pituitary insufficiency
Hypothyroxinemia of prematurity
Chronic systemic illness (euthyroid sick syndrome)
Constitutional growth delay

12. Summary Table

Feature	Congenital	Acquired
Onset	Birth	Childhood/adolescence
Cause	Dysgenesis > dyshormonogenesis	Hashimoto’s most common
Presentation	Lethargy, constipation, macroglossia	Growth failure, delayed puberty
TSH	High	High
T4	Low	Low
Rx	Levothyroxine	Levothyroxine
Prognosis	Excellent if early	Excellent

References

Nelson Textbook of Pediatrics, 22nd ed.
Indian Academy of Pediatrics Guidelines (2021) — Screening and management of congenital hypothyroidism.
Endocrine Society Clinical Practice Guideline (2020) – Congenital Hypothyroidism.
Sperling MA, Pediatric Endocrinology, 5th ed.

Nephrotic Syndrome Video For MD Pediatrics

Thank you For watching.

Here are related videos and articles

Leishmaniasis (Complete Notes)

Leishmaniasis — MD Pediatrics Note (Based on Nelson Textbook of Pediatrics)

~~Table of Contents(toc)~~

Introduction

Leishmaniasis is a spectrum of protozoal diseases caused by Leishmania species, transmitted by the bite of infected female phlebotomine sandflies.

cutaneous leishmaniasis

Disease manifestations depend on the species involved and the host immune response.
Major clinical forms:
1. Visceral leishmaniasis (VL / kala-azar)
2. Cutaneous leishmaniasis (CL)
3. Mucocutaneous leishmaniasis (MCL)

Etiology and Classification

Form	Causative Species	Geographic Distribution
Visceral	L. donovani, L. infantum (chagasi)	South Asia, East Africa, Latin America
Cutaneous	L. tropica, L. major, L. mexicana, L. braziliensis	Middle East, Africa, Americas
Mucocutaneous	L. braziliensis complex	Central & South America

Epidemiology

Endemic in >80 countries; affects poor, rural populations.
Vectors: Phlebotomus (Old World), Lutzomyia (New World).
Reservoirs: Humans (L. donovani), dogs, rodents.
Transmission: Sandfly bite, rarely congenital or via transfusion.

Phlebotomus

Pathogenesis

Inoculation of promastigotes → engulfed by macrophages → transform into amastigotes → intracellular multiplication → spread to RES (liver, spleen, bone marrow).
Disease severity depends on cell-mediated immunity (CMI).

Strong CMI → localized CL.
Poor CMI → disseminated VL.

lifecycle of L donovani

Clinical Features

A. Visceral Leishmaniasis (Kala-azar)

Incubation: 2 weeks–18 months.

Visceral Leishmaniasis (Kala-azar)

Onset: Insidious.
Major triad:
1. Fever: Remittent, double-quotidian, or irregular.
2. Hepatosplenomegaly: Marked splenomegaly, moderate hepatomegaly.
3. Pancytopenia: due to hypersplenism and marrow infiltration.
Other features:
- Weight loss, wasting, darkening of skin (“kala-azar” = black fever)
- Lymphadenopathy (esp. African form)
- Anemia, bleeding, infections (esp. bacterial superinfection)
- Growth retardation and cachexia in chronic disease.

Post-kala-azar dermal leishmaniasis (PKDL):

Occurs months–years after VL cure.
Hypopigmented macules, papules, nodules (face, arms, trunk).
Serves as a reservoir in endemic areas (notably India).

B. Cutaneous Leishmaniasis

Lesion: Painless papule → ulcer with indurated margin (“oriental sore”).
Usually heals spontaneously in 3–6 months but leaves scar.
Chronic forms may resemble lupus vulgaris.

C. Mucocutaneous Leishmaniasis

Extension from cutaneous lesion (nasal/oral mucosa).
Causes destructive ulcerations → severe disfigurement.

mucocutaneous leishmaniasis

Laboratory Diagnosis

1. Direct demonstration

Amastigotes (Leishman–Donovan bodies) in:
- Splenic aspirate (most sensitive, but risky)
- Bone marrow aspirate (safe, moderately sensitive)
- Lymph node or buffy coat smear
Giemsa-stained smears show:
- Oval amastigotes (2–5 μm) with nucleus and kinetoplast inside macrophages.

2. Culture

Novy–MacNeal–Nicolle (NNN) medium → promastigote growth.

3. Serologic tests

rK39 dipstick test: Highly sensitive & specific for VL (field use).
Direct agglutination test (DAT), IFA, ELISA also available.

4. Molecular tests

PCR: Highly sensitive, species-specific; used in reference labs.

5. Hematology

Pancytopenia, hypergammaglobulinemia, elevated ESR.

Treatment

First-line (Visceral Leishmaniasis)

Liposomal Amphotericin B (preferred):
- Total dose 10–21 mg/kg (varies by region/protocol)
- Short-course regimens effective.
Alternative:
- Amphotericin B deoxycholate: 1 mg/kg/day × 15–20 doses (toxic, nephrotoxic)
- Miltefosine: 2.5 mg/kg/day (max 150 mg/day) × 28 days (oral)
- Paromomycin (IM): 11 mg/kg/day × 21 days
- Combination regimens (to prevent resistance):
  - Single-dose liposomal amphotericin B + short-course miltefosine or paromomycin.

Cutaneous Leishmaniasis

Local therapy (cryotherapy, intralesional antimony) for small lesions.
Systemic therapy for multiple, mucosal, or immunocompromised cases:
- Miltefosine, liposomal amphotericin B, or pentavalent antimonials.

Mucocutaneous Leishmaniasis

Liposomal amphotericin B or pentavalent antimonials for ≥28 days.

Prevention and Control

Vector control: Insecticide spraying, bed nets.
Reservoir control: Treat dogs, cull infected reservoirs.
Personal protection: Repellents, protective clothing.
Early diagnosis and treatment reduce transmission.
Vaccine: None yet in routine use; trials ongoing.

Complications

Secondary bacterial infections
Severe anemia, hemorrhage
Disseminated infection in HIV patients
PKDL (in endemic regions like India/Nepal)

Prognosis

Excellent with prompt diagnosis and treatment.
Mortality >90% if untreated (mainly from secondary infections, cachexia).

Key Points from Nelson

Visceral leishmaniasis should be suspected in any febrile child with splenomegaly and pancytopenia in an endemic area.
rK39 test is the diagnostic test of choice in field settings.
Liposomal amphotericin B is the preferred therapy in both immunocompetent and immunocompromised children.
PKDL represents an important reservoir for ongoing transmission.
HIV co-infection complicates disease course and increases relapse risk.

Fanconi Anemia Notes for Doctors and PG Aspirants

Fanconi Anemia (FA)

~~Table of Contents(toc)~~

Category: Inherited bone marrow failure syndrome (IBMFS)
Inheritance: Autosomal recessive (rarely X-linked)
Gene defects: >22 genes identified (FANCA, FANCC, FANCG most common) → defective DNA interstrand crosslink repair.

fanconi anemia notes

1. Pathophysiology

Defect in DNA repair (Fanconi/BRCA pathway) → chromosomal breakage and hypersensitivity to DNA cross-linking agents (e.g., mitomycin C, diepoxybutane).
Progressive bone marrow failure (due to stem cell depletion) and genomic instability → predisposition to malignancies.
Multisystem developmental abnormalities due to impaired cell proliferation during embryogenesis.

2. Epidemiology

Incidence: ~1 in 100,000–250,000 live births.
Carrier frequency: ~1 in 200.
Median age of diagnosis: 7–9 years.
~90% develop marrow failure by age 40.

3. Clinical Features

A. Hematologic

Pancytopenia (usually first manifests with thrombocytopenia or macrocytic anemia).
Progressive bone marrow hypoplasia.
Increased fetal hemoglobin (HbF).
Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) risk ↑ markedly.

B. Physical anomalies (present in ~75%)

Growth: Short stature, low birth weight.
Skeletal: Radial ray defects—absent/hypoplastic thumb, radius anomalies.
Skin: Café-au-lait spots, hypopigmentation, hyperpigmentation.
Head/Face: Microcephaly, triangular face, microphthalmia.
Genitourinary: Renal agenesis, horseshoe kidney, hypoplastic gonads, undescended testes, infertility.
Cardiac: Structural heart defects.
ENT: Hearing loss.
GI: Duodenal atresia, anal anomalies (occasionally).

C. Endocrine/Metabolic

Hypothyroidism, glucose intolerance, gonadal failure, low IGF-1.

D. Malignancy risk

AML, MDS, and solid tumors (esp. head & neck SCC, gynecologic SCC, liver tumors) due to chromosomal instability.

4. Investigations

Test	Finding/Use
CBC	Pancytopenia, macrocytosis, increased HbF
Bone marrow biopsy	Hypocellular marrow with fatty replacement
Chromosomal breakage test	Diagnostic — increased breaks after exposure to diepoxybutane (DEB) or mitomycin C
Molecular genetic testing	Confirms FANCA–FANC gene mutations
Flow cytometry for CD34	Decreased hematopoietic stem cells
Ultrasound abdomen	Renal anomalies
Endocrine profile	Hypothyroidism, gonadal failure screening

5. Differential Diagnosis

Acquired aplastic anemia
Dyskeratosis congenita
Shwachman-Diamond syndrome
Diamond–Blackfan anemia

6. Management

Supportive

Regular CBC monitoring.
Transfusion support (RBCs, platelets) — minimize iron overload.
Iron chelation therapy if ferritin ↑.
Androgens (e.g., oxymetholone, danazol) → stimulate erythropoiesis (transient benefit).
G-CSF for neutropenia (short-term).
Avoid DNA-damaging agents (chemotherapy, radiation).

Curative

Allogeneic hematopoietic stem cell transplantation (HSCT) — only curative therapy for marrow failure.
- Ideal: HLA-matched sibling donor.
- Conditioning regimens: low-intensity to minimize toxicity (avoid alkylators, irradiation).

Malignancy surveillance

Annual oral, gynecologic, and dermatologic exams.
CBC every 3–6 months.
Avoid smoking, alcohol, and UV exposure.

Endocrine and developmental care

Hormonal replacement as indicated (thyroid, sex steroids, GH).
Orthopedic/surgical correction for congenital anomalies.

7. Prognosis

Median survival (without HSCT): ~20–30 years.
With HSCT: markedly improved, though risk of secondary malignancy persists.
Lifelong surveillance for cancer and organ dysfunction required.

8. Key Points for Exams

Classic triad: Bone marrow failure + congenital anomalies + cancer predisposition.
Diagnostic hallmark: Chromosomal breakage test positive with DEB/Mitomycin C.
Curative therapy: HSCT.
Common mutation: FANCA.
AML/MDS risk: markedly increased.
Androgens improve counts transiently but cause virilization/hepatotoxicity.